{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:11:20Z","timestamp":1793362280290,"version":"4.5.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"DOI":"10.3389\/fpubh.2026.1767210","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T06:39:55Z","timestamp":1769668795000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Improving access to psilocybin-assisted therapy: barriers, challenges, and recommendations"],"prefix":"10.3389","volume":"14","author":[{"given":"Vivian W. L.","family":"Tsang","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, University of British Columbia","place":["Vancouver, BC, Canada"]},{"name":"Evidence Based Healthcare, University of Oxford","place":["Oxford, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Roney","sequence":"additional","affiliation":[{"name":"Undergraduate Medical Program, Faculty of Medicine, University of British Columbia","place":["Vancouver, BC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Kryskow","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Faculty of Medicine, University of British Columbia","place":["Vancouver, BC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Dames","sequence":"additional","affiliation":[{"name":"Health and Human Services, Vancouver Island University","place":["Nanaimo, BC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/02791072.2023.2211516","article-title":"Psilocybin's potential mechanisms in the treatment of depression: a systematic review","volume":"55","author":"Tsang","year":"2023","journal-title":"J Psychoactive Drugs."},{"key":"B2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1136\/bmjspcare-2019-001986","article-title":"Mental healthcare and palliative care: barriers","volume":"11","author":"O'Malley","year":"2021","journal-title":"BMJ Support Palliative Care."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1568017","DOI":"10.3389\/fpsyt.2025.1568017","article-title":"A clinical protocol for group-based ketamine-assisted therapy in a community of practice: the Roots to Thrive model","volume":"16","author":"Dames","year":"2025","journal-title":"Front Psychiatry."},{"key":"B5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1089\/psymed.2023.0004","article-title":"Psychedelic-assisted therapy training: an argument in support of firsthand experience of nonordinary states of consciousness in the development of competence","volume":"2","author":"Dames","year":"2024","journal-title":"Psychedelic Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","first-page":"CD011006","DOI":"10.1002\/14651858.CD011006.pub2","article-title":"Antidepressants for the treatment of depression in people with cancer","volume":"6","author":"Ostuzzi","year":"2015","journal-title":"Cochr Database Syst Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology."},{"key":"B9","volume-title":"OurCare: A National Survey of Primary Care Access and Experiences in Canada","author":"Kiran","year":"2022"},{"key":"B10","volume-title":"Special Access Program for Drugs. Special Access Program Guidance Document","year":"2020"},{"key":"B11","doi-asserted-by":"publisher","first-page":"20451253251356980","DOI":"10.1177\/20451253251356980","article-title":"Ketamine-assisted therapy within a community of practice: A novel approach to disordered eating","volume":"15","author":"Jeletzky","year":"2025","journal-title":"Ther Adv Psychopharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/02791072.2023.2253798","article-title":"A pilot study comparing a community of practice program with and without concurrent ketamine-assisted therapy","volume":"56","author":"Tsang","year":"2023","journal-title":"J Psychoactive Drugs."},{"key":"B13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1556\/2054.2024.00379","article-title":"\u201cThe mushroom was more alive and vibrant\u201d: Patient reports of synthetic versus organic forms of psilocybin","volume":"8","author":"Kryskow","year":"2024","journal-title":"J Psychedelic Stud."},{"key":"B14","author":"Stamets","year":"2025","journal-title":"Personal Communication"},{"key":"B15","unstructured":"Notice to stakeholders: Requests to the Special Access Program (SAP) Involving Psychedelic-Assisted Psychotherapy\n          \n          2023"},{"key":"B16","unstructured":"Notice to Stakeholders: Health Canada's Expectations Regarding Risk-Management Measures for Clinical Trials Involving Psychedelic-Assisted Psychotherapy\n          \n          2022"},{"key":"B17","unstructured":"Special Access Program for Drugs: Guidance Document for Industry and Practitioners\n          \n          2020"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e372","DOI":"10.1097\/JOM.0000000000003352","article-title":"The effect of ketamine-assisted group therapy on treatment-resistant mental health conditions in firefighters: a prospective observational case series","volume":"67","author":"Tsang","year":"2025","journal-title":"J Occup Environ Med."},{"key":"B19","author":"Peekakoot","year":"2025","journal-title":"Personal Communication"},{"key":"B20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/JOM.0000000000003579","article-title":"Ketamine-assisted therapy outcomes for first-responders with comorbid mental health diagnoses","author":"Tsang","year":"2025","journal-title":"J Occup Environ Med."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1767210\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T06:39:58Z","timestamp":1769668798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1767210\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":20,"alternative-id":["10.3389\/fpubh.2026.1767210"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1767210","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"article-number":"1767210"}}